Crinetics Pharmaceuticals presented long-term data from PATHFNDR-1 and PATHFNDR-2 studies showing that PALSONIFY (paltusotine), an oral once-daily treatment for acromegaly, maintained stable IGF-1 levels, controlled symptoms, and stabilized or reduced pituitary tumor volumes over up to two years. The drug was well tolerated with manageable side effects. Additional data showed that combining PALSONIFY with cabergoline improved biochemical control in patients. These results support PALSONIFY as an effective oral alternative to injectable treatments for adults with acromegaly, potentially improving patient quality of life and treatment adherence.
HBAR's price is trading in a tight range between $0.085 support and $0.095 resistance, influenced by large whale OTC transactions totaling $250 million ahead of a major network upgrade. This activity has balanced liquidity and kept volatility low, wi...
VELVET, a thin-liquidity altcoin, surged about 885% in one week and 165% in 24 hours over a weekend, driven by low market depth and leveraged derivatives trading. The rapid price rise attracted traders chasing high returns in smaller tokens during a ...
World Liberty Financial (WLFI), a crypto firm co-founded by Donald Trump, is sponsoring $250,000 in stablecoin bonuses at the UFC Freedom 250 event held at the White House. The bonuses, paid in WLFI's USD1 stablecoin, are part of a record $1.65 milli...
Aerodrome, the largest decentralized exchange on Coinbase’s Base network, will replace its weekly voting system with a new Predictive Allocation model in July 2026. This system rewards participants who accurately forecast future liquidity demand by g...
Celldex Therapeutics presented long-term Phase 2 results showing barzolvolimab provides rapid, significant, and durable relief from angioedema in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines. Impre...
